Based on the key indicators related to Viridian Therapeutics' liquidity, profitability, solvency, and operating efficiency, Viridian Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Viridian Therapeutics' Cash is very stable compared to the past year. As of the 24th of March 2025, Non Currrent Assets Other is likely to grow to about 972.3 K, while Current Deferred Revenue is likely to drop about 246.2 K. Key indicators impacting Viridian Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Viridian Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Viridian Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Viridian Therapeutics.
Viridian Therapeutics competes with Day One, Replimune, Mirum Pharmaceuticals, Rocket Pharmaceuticals, and Avidity Biosciences. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts. Viridian Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Viridian Therapeutics's current stock value. Our valuation model uses many indicators to compare Viridian Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Viridian Therapeutics competition to find correlations between indicators driving Viridian Therapeutics's intrinsic value. More Info.
Viridian Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Viridian Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viridian Therapeutics' earnings, one of the primary drivers of an investment's value.
Viridian Therapeutics Systematic Risk
Viridian Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Viridian Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Viridian Therapeutics correlated with the market. If Beta is less than 0 Viridian Therapeutics generally moves in the opposite direction as compared to the market. If Viridian Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Viridian Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Viridian Therapeutics is generally in the same direction as the market. If Beta > 1 Viridian Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Viridian Therapeutics Thematic Clasifications
Viridian Therapeutics is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Viridian Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Viridian Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Viridian Therapeutics growth as a starting point in their analysis.
Viridian Therapeutics March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Viridian Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Viridian Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Viridian Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Viridian Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Viridian Therapeutics's daily price indicators and compare them against related drivers.
When determining whether Viridian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viridian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viridian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viridian Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.07)
Revenue Per Share
0.004
Return On Assets
(0.30)
Return On Equity
(0.48)
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.